CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2023—LGC SeraCare has developed three contrived, tumor normal cell-line–derived homologous recombinant deficiency reference materials: Seraseq FFPE HRD High-Positive RM, Seraseq FFPE HRD Low-Positive RM, and Seraseq FFPE HRD Negative RM.
The products aim to support the development, validation, and routine determination of HRD status in patients who have cancer. The materials are derived from tumor and matched normal cell lines blended at approximately 65 percent tumor content. One 10-μm FFPE curl is provided per vial, and the product is designed to give a minimum yield of 100 ng per curl.
Pages: 1 2